Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer (TA406)

Technology Appraisal Guidance No. 406

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Crizotinib is recommended, within its marketing authorisation, as an option for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults. The drug is recommended only if the company provides it with the discount agreed in the patient access scheme.

     


    The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at 

    This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

    © Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

    Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: [email protected]

    Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

    Issue Date: September 2016


    Have you registered with us yet?

    Register now to enjoy more articles and free email bulletins

    Already registered?
    Sign in

    More from intelog

    New antibiotic prescribing guidance issued for pneumonia

    New antibiotic prescribing guidance issued for pneumonia

    NICE has published antimicrobial prescribing guidelines...

    intelog summary of NICE COPD guidance updated

    intelog summary of NICE COPD guidance updated

    Prescribers can now consult the quick-reference intelog...

    Soft-mist inhaler now available as reusable device

    Soft-mist inhaler now available as reusable device

    Respimat is now available as a reusable inhaler that...

    NICE recommends 'innovative' treatment for type I diabetes

    NICE recommends 'innovative' treatment for type I diabetes

    Dapagliflozin (Forxiga) has been approved for routine...